Compare Amgen, Inc. (AMGN) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Wheaton Precious Metals Corp — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Wheaton Precious Metals Corp trades at $108.75 (market cap $49.85B). The key difference: Amgen, Inc. is far larger — about 3.9× Wheaton Precious Metals Corp's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | WPM | |
|---|---|---|
Market Cap | $196.12B | $49.85B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $165.72 |
52-Week Low | $271.18 | $88.32 |
Enterprise Value | $241.41B | $47.69B |
Dividend Yield | 2.77% | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Wheaton Precious Metals (WPM) trades at $110.05, down 0.54% on the day, amid a bearish technical signal. The company exhibits strong fundamentals with 2025 revenue of $2.31B, net income of $1.47B, and consistent earnings beats. Analyst consensus is strongly bullish with a $163 price target, though recent news highlights sensitivity to precious metal price volatility.
WPM offers a compelling growth story with robust profitability and positive cash flow, but faces risks from commodity price swings and acquisition integration. The stock's current discount to analyst targets presents a potential opportunity for long-term investors, contingent on stable metal prices and execution of production outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
